The Priority Review

Tag

GL Pharm Tech Corporation

1 story

  1. Clinical trials

    GL Pharm Tech Corporation registers Phase 3 trial of W2505 for erectile dysfunction

    The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 228 participants and begin in September 2026. It is a prospective, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of W2505.